Physician profile
Cristos MD Ifantides
NPI 1821356676
$342,945.56
in general payments reported to CMS, 2019-2025
27 companies · $198K in 2025
The $198K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,904 · 2020: $79.90 · 2021: $5,865 · 2022: $19K · 2023: $16K · 2024: $96K · 2025: $198K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $205K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Food and Beverage: $11K · Travel and Lodging: $8,051 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $205,039.55 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,525.00 |
| Food and Beverage | $11,167.59 |
| Travel and Lodging | $8,051.11 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $193,419.26 | 2024-2025 | Xdemvy |
| Alcon Research LLC | $43,019.30 | 2022-2025 | Clareon, Acrysof Iq Vivity, Acrysof Iq Panoptix Uv Iol |
| Alcon Vision LLC | $38,869.56 | 2019-2025 | Acrysof Iq Panoptix Uv Iol, Clareon, Centurion |
| Abbvie INC. | $13,009.10 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $11,778.70 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $9,851.33 | 2023-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| New World Medical,INC. | $6,325.25 | 2019-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Via360 |
| Sight Sciences, INC. | $5,933.75 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Carl Zeiss Meditec USA, INC. | $4,693.52 | 2021-2024 | Quatera 700, Iolmaster 700, Veracity Surgical |
| Dompe US, INC. | $3,537.80 | 2022-2025 | Oxervate |
| Lensar, INC. | $3,457.73 | 2022-2025 | Lensar Laser System |
| Carl Zeiss Meditec, INC. | $3,132.88 | 2022-2025 | Forum, Iolmaster 700, Humphrey Hfa |
| Allergan, INC. | $2,649.23 | 2019-2022 | |
| Glaukos Corporation | $1,098.55 | 2022-2025 | Idosetr, Istent Infinite, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Beaver-Visitec International, INC. | $500.00 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $425.76 | 2019-2025 | Cequa |
| Microsurgical Technology, INC. | $329.83 | 2025 | |
| Carl Zeiss Meditec Cataract Technology INC. | $253.16 | 2023-2024 | |
| Ocular Therapeutix, INC. | $205.87 | 2020-2025 | Dextenza |
| Dutch Ophthalmic, USA | $168.61 | 2024 | Tissueblue, Eva, Combined Machine |
| Rayner Intraocular Lenses Limited | $98.64 | 2024-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Kala Pharmaceuticals, INC. | $46.24 | 2022 | |
| Novartis Pharmaceuticals Corporation | $42.43 | 2021 | |
| Omeros Corporation | $34.07 | 2019 | |
| Rxsight INC | $25.59 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $20.00 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cristos Ifantides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.